How to buy Johnson And Johnson (JNJ) shares in Australia
Learn how to easily invest in Johnson And Johnson shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Johnson & Johnson is a drug manufacturers-general business with stocks listed in the US. Johnson And Johnson shares (JNJ) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$164.08 – an increase of 0.13% over the previous week. Here's how to invest if you're based in Australia.
How to buy shares in Johnson And Johnson
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Johnson And Johnson. Find the share by name or ticker symbol: JNJ. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Johnson And Johnson reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$163.72, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Johnson And Johnson, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Johnson And Johnson. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Johnson And Johnson key stats
- Compare share trading platforms
- Is Johnson And Johnson stock a buy or sell?
- Johnson And Johnson performance over time
- Can I short Johnson And Johnson shares?
- Is Johnson And Johnson suitable for ethical investing?
- Are Johnson And Johnson shares over-valued?
- Johnson And Johnson's financials
- How volatile are Johnson And Johnson shares?
- Does Johnson And Johnson pay a dividend?
- Have Johnson And Johnson shares ever split?
- Other common questions
Johnson And Johnson stock price (NYSE:JNJ)Use our graph to track the performance of JNJ stocks over time.
Johnson And Johnson shares at a glance
|52-week range||US$130.313 - US$178.93|
|50-day moving average||US$163.662|
|200-day moving average||US$167.3565|
|Dividend yield||US$4.14 (2.53%)|
|Earnings per share (TTM)||US$6.691|
Where to buy Johnson And Johnson stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Johnson And Johnson stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Johnson And Johnson shares?Before you consider Johnson And Johnson, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Johnson And Johnson price performance over time
|1 week (2021-10-18)||2.47%|
|1 month (2021-09-24)||-0.17%|
|3 months (2021-07-26)||-4.53%|
|6 months (2021-04-26)||-0.02%|
|1 year (2020-10-26)||13.97%|
|2 years (2019-10-25)||27.84%|
|3 years (2018-10-26)||19.79%|
|5 years (2016-10-26)||43.23%|
Stocks similar to Johnson And Johnson
Is Johnson And Johnson under- or over-valued?
Valuing Johnson And Johnson stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Johnson And Johnson's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Johnson And Johnson's P/E ratio
Johnson And Johnson's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Johnson And Johnson shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Johnson And Johnson's PEG ratio
Johnson And Johnson's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6376. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Johnson And Johnson's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Johnson And Johnson's EBITDA
Johnson And Johnson's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$31.3 billion (£22.7 billion).
The EBITDA is a measure of a Johnson And Johnson's overall financial performance and is widely used to measure a its profitability.
Johnson And Johnson financials
|Revenue TTM||US$91.4 billion|
|Operating margin TTM||26.07%|
|Gross profit TTM||US$54.3 billion|
|Return on assets TTM||8.65%|
|Return on equity TTM||-9999999%|
|Market capitalisation||US$431 billion|
TTM: trailing 12 months
Shorting Johnson And Johnson shares
There are currently 16.3 million Johnson And Johnson shares held short by investors – that's known as Johnson And Johnson's "short interest". This figure is 0.3% down from 16.4 million last month.
There are a few different ways that this level of interest in shorting Johnson And Johnson shares can be evaluated.
Johnson And Johnson's "short interest ratio" (SIR)
Johnson And Johnson's "short interest ratio" (SIR) is the quantity of Johnson And Johnson shares currently shorted divided by the average quantity of Johnson And Johnson shares traded daily (recently around 6.2 million). Johnson And Johnson's SIR currently stands at 2.64. In other words for every 100,000 Johnson And Johnson shares traded daily on the market, roughly 2640 shares are currently held short.
However Johnson And Johnson's short interest can also be evaluated against the total number of Johnson And Johnson shares, or, against the total number of tradable Johnson And Johnson shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Johnson And Johnson's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Johnson And Johnson shares in existence, roughly 10 shares are currently held short) or 0.0062% of the tradable shares (for every 100,000 tradable Johnson And Johnson shares, roughly 6 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Johnson And Johnson.
Find out more about how you can short Johnson And Johnson stock.
Johnson And Johnson's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Johnson And Johnson.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Johnson And Johnson's total ESG risk score
Total ESG risk: 35.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Johnson And Johnson's overall score of 35.8 (as at 12/31/2018) is pretty weak – landing it in it in the 72nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Johnson And Johnson is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Johnson And Johnson's environmental score
Environmental score: 3.79/100
Johnson And Johnson's environmental score of 3.79 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Johnson And Johnson's social score
Social score: 25.14/100
Johnson And Johnson's social score of 25.14 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Johnson And Johnson is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Johnson And Johnson's governance score
Governance score: 14.87/100
Johnson And Johnson's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Johnson And Johnson is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Johnson And Johnson's controversy score
Controversy score: 4/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Johnson And Johnson scored a 4 out of 5 for controversy – the second-lowest score possible, reflecting that Johnson And Johnson has a damaged public profile.
Environmental, social, and governance (ESG) summary
|Total ESG score||35.8|
|Total ESG percentile||72.38|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||4|
Johnson And Johnson share dividends
Dividend payout ratio: 35.72% of net profits
Recently Johnson And Johnson has paid out, on average, around 35.72% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.59% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Johnson And Johnson shareholders could enjoy a 2.59% return on their shares, in the form of dividend payments. In Johnson And Johnson's case, that would currently equate to about $4.14 per share.
While Johnson And Johnson's payout ratio might seem fairly standard, it's worth remembering that Johnson And Johnson may be investing much of the rest of its net profits in future growth.
Johnson And Johnson's most recent dividend payout was on 6 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 August 2021 (the "ex-dividend date").
Have Johnson And Johnson's shares ever split?
Johnson And Johnson's shares were split on a 2:1 basis on 12 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Johnson And Johnson shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Johnson And Johnson shares which in turn could have impacted Johnson And Johnson's share price.
Johnson And Johnson share price volatility
Over the last 12 months, Johnson And Johnson's shares have ranged in value from as little as US$130.313 up to US$178.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Johnson And Johnson's is 0.7201. This would suggest that Johnson And Johnson's shares are less volatile than average (for this exchange).
Johnson And Johnson overview
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson And Johnson in the news
Johnson & Johnson: Currently Trading At Fair To Overvalued Territory
New Analyses Suggest Favorable Results for STELARA (ustekinumab) When Used as a First-Line Therapy for Bio-Naive Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis
Cramer: ‘Stop freaking out’ about inflation — here's how to profit from soaring costs
Frequently asked questions
More guides on Finder
Why is the AMP share price looking up today?
Shares in the wealth management giant have been largely stable in the last 6 months.
How to invest in the Judo Capital Holdings IPO
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
How to invest in the Alloggio Group IPO
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
How to invest in the Larvotto Resources IPO
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
How to invest in the Vulcan Steel IPO
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
How to invest in the Artrya IPO
Everything we know about the Artrya IPO, plus information on how to buy in.
How to invest in the 8 Au IPO
Everything we know about the 8 Au IPO, plus information on how to buy in.
How to invest in the Radiopharm Theranostics IPO
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
What has prompted the rebound in the Kogan share price?
The online retailer’s shares have lost more than half their value in the last 12 months.
How to buy GQG Partners shares
Steps to owning and managing GQG Partners shares.
Ask an Expert